ALSO READStrides Shasun gains amid high volumes after receiving USFDA approval for drug Bal Pharma gains on mulling key business propositions NIIT gains as global pharma company extends training services contract MPS spurts after announcing completion of Magplus acquisition Dishman Pharma gains as Swiss unit completes USFDA inspection for 2 sites
Strides Shasun rose 1.06% to Rs 1,091.95 at 10:14 IST on BSE after the company said its UK-based subsidiary will acquire PediaCare brand from Sweden's Moberg Pharma for $5 million plus inventory value at closing.The announcement was made after market hours on Friday, 25 November 2016.
Meanwhile, the BSE Sensex was down 67.76 points, or 0.26%, to 26,248.58.
On BSE, so far 9,778 shares were traded in the counter, compared with average daily volume of 67,539 shares in the past one quarter. The stock hit a high of Rs 1,100 and a low of Rs 1,077 so far during the day. The stock hit a 52-week high of Rs 1,400 on 10 December 2015. The stock hit a 52-week low of Rs 848 on 29 February 2016.
The stock had outperformed the market over the past 30 days till 25 November 2016, rising 14.98% compared with the 5.73% decline in the Sensex. The scrip had also outperformed the market in past one quarter, rising 13.44% as against Sensex's 5.28% decline.
The mid-cap company has equity capital of Rs 89.37 crore. Face value per share is Rs 10.
Strides Shasun announced that its wholly-owned subsidiary Strides Arcolab International, UK has entered into an agreement with Moberg Pharma, Sweden to acquire the 'PediaCare' brand for a total consideration of $5 million plus inventory value at closing.
PediaCare is an established paediatric cough, cold and allergy brand with annual sales of approximately $6 million. PediaCare will form an important part of Strides expanding consumer health care portfolio and brings with it expertise in the paediatric segment as well as a strong brand name with global potential.
Strides Shasun's consolidated net profit rose 106.90% to Rs 74.09 crore on 36.26% rise in net sales to Rs 922.17 crore in Q2 September 2016 over Q2 September 2015.
Strides Shasun is a vertically integrated global pharmaceutical company headquartered in Bangalore.
Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)